IGC Pharma, Inc. (NYSE: IGC) CEO Ram Mukunda recently discussed the company’s clinical progress, AI initiatives, and long-term strategy on The Street Reports Podcast. Mukunda highlighted IGC Pharma’s lead Phase 2 Alzheimer’s drug candidate, IGC-AD1, which is being evaluated in the ongoing CALMA clinical trial for agitation associated with Alzheimer’s dementia.
AI Initiatives
IGC Pharma is also investing in Artificial Intelligence, including its proprietary Agentic Harmonization Assistant (AHA) platform. In internal testing, AHA reduced Alzheimer’s research data processing time by approximately 90%, helping researchers organize complex biomedical data and potentially accelerating drug discovery, clinical research, and precision medicine initiatives.
The company is preparing to showcase AHA at the Alzheimer’s Association International Conference (AAIC) 2026 in London, where they expect to demonstrate how AI can improve biomedical data integration and support faster pharmaceutical research.
IGC Pharma is advancing a pipeline of Alzheimer’s therapeutic candidates, including TGR-63, while expanding AI-enabled technologies designed to support machine learning, clinical trial optimization, and healthcare analytics.
Original reporting: KTBS 3 (Shreveport) — read the source article.
